Clinical trials: Alcohol-Related Liver Disease
Hepatitis, Alcoholic
Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis
Hypothesis: Oral administration of hyperimmune bovine colostrum enriched with anti-LPS antibodies will reduce endotoxemia, and improve pathophysiological and clinical parameters related to severe alcoholic hepatitis (SAH).
- Trial name
- TREAT (NCT01968382)
- Testing
- IMM 124-E (Hyperimmune Bovine Colostrum)
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Virginia Commonwealth University
Alcoholic Liver Disease
Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients
This is a research study of a text-messaging intervention to reduce alcohol relapse risk in pre-transplant liver transplantation patients.
- Trial name
- NCT03402256
- Testing
- Text Message
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Yale University
Alcohol Hepatitis
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)
- Trial name
- NCT06685692
- Testing
- ADX-629
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- Aldeyra Therapeutics, Inc.
NAFLD, Alcohol-Related Disorder
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients (IMPROVE Study)
The main objective is to determine the performance of the simple eLIFT blood test for advanced liver fibrosis screening in NAFLD and/or alcoholic patients in primary care.
- Conditions
- NAFLD, Alcohol-Related Disorder, Liver Fibrosis
- Trial name
- IMPROVE (NCT04146636)
- Testing
- e-LIFT
- Where
- France
- Volunteers
- 282 people
- Sponsor
- University Hospital, Angers
Alcoholic Liver Diseases, Decompensated Cirrhosis
Biomarkers for the Prognosis of Decompensated Alcoholic Liver Disease
Fibroscan is a non invasive imaging investigation which measures liver stiffness, known to correlate well with liver scarring and cirrhosis on liver biopsy.
- Trial name
- BANDED (NCT01701687)
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- University of Nottingham
Alcohol Related Disorders
Hepatic Function During and Following Three Days of Acetaminophen Dosing in Alcoholics
The study objective was to determine whether liver injury develops in alcoholic patients who ingest therapeutic doses of APAP for three consecutive days.
- Trial name
- NCT00402571
- Testing
- acetaminophen
- Where
- 2 sites in United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Denver Health and Hospital Authority
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Cohort Study
Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN-C (NCT05740358)
- Where
- 14 sites in United States
- Volunteers
- 1,222 people
- Sponsor
- Northwestern University
Alcoholic Liver Cirrhosis
Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC
This study is to evaluate the safety and efficacy of a single dose of Cellgram™ delivered via hepatic artery in patients with decompensated alcoholic liver cirrhosis.
- Trial name
- NCT03838250
- Testing
- Cellgram™ (Bone marrow-derived MSCs)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Pharmicell Co., Ltd.
Alcoholic Hepatitis (AH)
Recompensation in Alcohol Related Hepatitis
Genetic activity and metabolic changes may be part of the pathogenesis in alcohol related hepatitis. We do not know exactly how alcohol cessation affects liver functions and metabolism.
- Trial name
- A-HEP (NCT06740318)
- Testing
- Motivational enhancement therapy
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Nina Kimer
Alcohol Dependence, Chronic Hepatitis C
Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients
The purpose of this study is to determine whether motivational enhancement therapy (MET) reduces alcohol use in a population of HCV-infected veterans who are currently drinking alcohol and have alcohol disorders.
- Trial name
- NCT00596960
- Testing
- Motivational Enhancement Therapy (MET), Health education
- Where
- 2 sites in United States
- Volunteers
- 139 people
- Sponsor
- US Department of Veterans Affairs
Hepatitis C, Substance Abuse
Psychoeducation for Hepatitis and Alcohol Behaviors
The proposed project will apply a unique, effective family-responsive psychoeducation program, PsychoEducation Responsive to Families (PERF), for Hepatitis C Virus (HCV) treatment.
- Trial name
- NCT00598416
- Testing
- Family-Responsive Psychoeducation Program (PERF)
- Where
- United States
- Volunteers
- 556 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Nonalcoholic Fatty Liver Disease, Light-to-moderate Alcohol Consumption
Alcohol Consumption and Type 2 Diabetes Mellitus Risk in Nonalcoholic Fatty Liver Disease
This study explored the cross-sectional and prospective associations between light-to-moderate alcohol consumption (LMAC) and risk of type 2 diabetes mellitus (T2DM) in individuals with nonalcoholic fatty liver disease (NAFLD).
- Conditions
- Nonalcoholic Fatty Liver Disease, Light-to-moderate Alcohol Consumption, Type2 Diabetes Mellitus
- Trial name
- NCT03847116
- Where
- China
- Volunteers
- 14,014 people, healthy volunteers welcome
- Sponsor
- Ningbo No. 1 Hospital
Alcoholic Cirrhosis, Alcoholic Liver Disease
Value on Survival of Liver Volume After an Acute Decompensation of an Alcoholic Cirrhosis
Investigator seek to determine whether the volume of the liver can predict the survival after a decompensation of a patient suffering from chronic liver disease caused by excessive alcohol consumption (or alcoholic cirrhosis).
- Trial name
- PROLIV (NCT03508388)
- Where
- France
- Volunteers
- 142 people
- Sponsor
- University Hospital, Montpellier
Hepatitis
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment…
- Trial name
- NCT07428538
- Testing
- Larsucosterol
- Where
- 92 sites in United States
- Volunteers
- 350 people
- Sponsor
- Bausch Health Americas, Inc.
Alcoholic Hepatitis
Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
The main purpose of the study is to test if taking a study drug called emricasan (also known as IDN-6556 and PF-03491390) will affect overall patient survival after one month of treatment.
- Trial name
- AH (NCT01912404)
- Testing
- IDN-6556
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Alcoholic Liver Disease
Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)
Recent years, the European Association for the Study of the Liver-chronic liver failure (EASL-CLIF) has defined and graded acute-on-chronic liver failure (ACLF) based on CANONIC study which enrolled cirrhotic patients with acute…
- Trial name
- SCALE (NCT03295812)
- Testing
- standard therapy
- Where
- 26 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Iron Overload, Metabolic Syndrome X
Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging
Iron excess is increasingly regarded as an important cofactor in the morbidity attributed to many disorders. Assessment of body iron stores by measurement of serum ferritin concentrations has poor specificity and the most…
- Conditions
- Iron Overload, Metabolic Syndrome X, Hepatitis B, Hepatitis C
- Trial name
- SURFER (NCT00401336)
- Testing
- Magnetic resonance imaging multiecho gradient-echo sequence
- Where
- 10 sites in France, Spain
- Volunteers
- 250 people
- Sponsor
- Rennes University Hospital
ALD - Alcoholic Liver Disease
Comparison of ALD, NASH, and Healthy Control Patients
The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in…
- Trial name
- NCT03224949
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Alcoholic Hepatitis
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).
- Trial name
- AHFIRM (NCT04563026)
- Testing
- DUR-928 30 mg, DUR-928 90 mg
- Where
- 68 sites in United States, Australia and 4 more
- Volunteers
- 307 people
- Sponsor
- Durect